ccr3 inhibitor  (MedChemExpress)

Journal: Drug Design, Development and Therapy

Article Title: Exploring the Potential of Pyridine Carboxylic Acid Isomers to Discover New Enzyme Inhibitors

doi: 10.2147/DDDT.S513461

Figure Lengend Snippet: Structures of CCR3 inhibitor 314 .

Article Snippet: US11,382,907B2 , Pyridine-4-carboxylic acid , Alkahest, Inc , Chemo kinase receptor 3 (CCR3) inhibitors/Methods for the improvement of neurodegenerative diseases including aging-associated-neuronal loss, aging-associated-loss of motor coordination, and aging-associated-memory impairment. , 2022 , [ ] .

Techniques:

Journal: NPJ Precision Oncology

Article Title: CCL11/CCR3-dependent eosinophilia alleviates malignant pleural effusions and improves prognosis

doi: 10.1038/s41698-024-00608-8

Figure Lengend Snippet: a Eosinophils from bone marrow and pleural lavage fluid at day 2 were sorted by MACS and FACS and subjected to RNA sequencing to profile gene expression. The enriched eosinophil chemotaxis pathway gene set is shown (NES = 1.846; NOM P = 0.003). b – h Blockade of CCR3 inhibited eosinophil recruitment, promoted pleural tumor growth, and increased MPE volume. b Experimental design of iCCR3. c Representative flow cytometry diagram of eosinophils in pleural lavage fluid. Eosinophils were identified as DAPI - CD45 + Gr1 -/low CD11c - CD11b + F4/80 + SiglecF + SSC hi cells. d , e Number of eosinophils and percentage of eosinophils/CD45 + cells. f Representative images of bioluminescence analysis. g , h Bioluminescence measured as photons per second (p/s) and effusion volume recorded. Data are mean ± SEM. Two-way ANOVA followed by Bonferroni test for ( d , e ) two-tailed unpaired Student’s t test for ( g , h ). P < 0.05 were considered significant ( n = 4 per group). Abbreviations: n.s . not significant.

Article Snippet: Small molecule C-C motif chemokine receptor 3 (CCR3) inhibitors SB297006 (Selleck, Cat#S0129) and corn oil (Solarbio LIFE SCIENCE, Cat#8001-30-7) as vehicle were delivered intraperitoneally at a dose of 5 mg/kg every 12 h. Peripheral blood (PB) and spleen eosinophils from Il5 Tg mice were resuspended in 200 μL of PBS and injected into the tail vein (5–10 × 10 6 eosinophils/per mouse).

Techniques: RNA Sequencing, Gene Expression, Chemotaxis Assay, Flow Cytometry, Two Tailed Test

Journal: International Journal of Molecular Sciences

Article Title: The Chemokine Receptor CCR3 Is Potentially Involved in the Homing of Prostate Cancer Cells to Bone: Implication of Bone-Marrow Adipocytes

doi: 10.3390/ijms22041994

Figure Lengend Snippet: CCR3 is an important driver in the directed migration of PCa cells towards BM-Ad-CM and its effect is majored in obesity and ageing conditions. In vitro migration of C4-2B ( A ) or PC3 ( B ) . CCR3 (UCB35625, 200 nM), CCR2 (sc-202525, 25 nM), CXCR1/2 (SB225002 inhibitor, 50 nM) or CXCR4 (AMD3100, 100 nM) or with mAbs against CCR3, CXCR1, CXCR2 or CXCR4 (all used at 10 μg/ml). Bar plots represent the percentage of migrating cells relative to the migration of untreated cells (set to 100%). Data are shown as mean ± sem ( n = 4–6). The statistical significance between means of migrating cells (in %) in treated vs. control cells was evaluated by One-way ANOVA with Tukey’s multiple comparisons test. Similar experiments were performed with the indicated cell lines towards BM-Ad-CM obtained either from lean/obese ( C ) or control/aged ( D ) subjects in the presence of CCR3 inhibitors and blocking mAb. Data are shown as mean ± sem ( n = 4–9). The statistical significance between mean of migrating cells (with the control groups set at 100%) was evaluated by Two-way ANOVA with Sidak’s multiple comparisons test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns: not significant.

Article Snippet: Cells were also pre-incubated for 30 min at 37 °C with pharmacological inhibitors: 200nM CCR1/CCR3 inhibitor, UCB35625 (Tocris, Bristol, UK), 25nM CCR2 inhibitor, sc-202525 (Santa Cruz Biotechnology, Dallas, TE, USA), 50nM CXCR1/2 inhibitor, SB225002 (Tocris, Bristol, UK) or 100nM CXCR4 inhibitor, AMD3100 (Sigma-Aldrich, Saint Louis, MO, USA).

Techniques: Migration, In Vitro, Control, Blocking Assay